5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

Detalles Bibliográficos
Autores principales:	Craddock, C, Goardon, N, Griffiths, M, Cavenagh, J, Siddique, S, Vyas, P
Formato:	Conference item
Publicado:	2008

Ejemplares similares

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS
por: Craddock, C, et al.
Publicado: (2009)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
por: Craddock, C, et al.
Publicado: (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
por: Craddock, C, et al.
Publicado: (2013)

Clonal structures of leukaemia stem cell populations in myeloid blast phase chronic myeloid leukaemia
por: Karamitros, D, et al.
Publicado: (2016)

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.
por: Bradbury, C, et al.
Publicado: (2014)

FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
por: Craddock, C, et al.
Publicado: (2010)

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia
por: Craddock, C, et al.
Publicado: (2011)

INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
por: Goodyear, O, et al.
Publicado: (2010)

Selective Persistence of Distinct Stem/B Leukaemic Stem Cells In Childhood Acute Lymphoblastic Leukaemia In Clinical Remission
por: Lutz, C, et al.
Publicado: (2010)

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
por: Goodyear, O, et al.
Publicado: (2010)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
por: Loke, J, et al.
Publicado: (2021)

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
por: Craddock, C, et al.
Publicado: (2016)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
por: Craddock, C, et al.
Publicado: (2017)

Genetic and epigenetic basis of clonal advantage during the evolution of acute myeloid leukaemia
por: Turkalj, S
Publicado: (2024)

Characterising early human lympho-myeloid haematopoietic progenitors and their relationship with acute myeloid leukaemia stem cells
por: Aboukhalil, Z
Publicado: (2018)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
por: Goodyear, O, et al.
Publicado: (2012)

Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
por: Jiang, Y, et al.
Publicado: (2021)

Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
por: Craddock, C, et al.
Publicado: (2017)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
por: Waldmann, H, et al.
Publicado: (1987)

Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.
por: Lutz, C, et al.
Publicado: (2013)

Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia
por: Lutz, C, et al.
Publicado: (2013)

Analysis of GATA-1 mutations in chronic myeloid leukaemia.
por: Halsey, C, et al.
Publicado: (2006)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
por: DiNardo, CD, et al.
Publicado: (2021)

GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome
por: Garnett, C, et al.
Publicado: (2019)

GATA1 mutational analysis in chronic myeloid leukaemia.
por: Halsey, C, et al.
Publicado: (2007)

Clonal haematopoiesis and risk of acute myeloid leukemia
por: Young, A, et al.
Publicado: (2019)

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.
por: Karamitros, D, et al.
Publicado: (2017)

Harnessing the graft-versus-leukaemia effect in acute myeloid leukaemia
por: Sweeney, C
Publicado: (2021)

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
por: Apperley, J, et al.
Publicado: (1986)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
por: Doehner, H, et al.
Publicado: (2017)

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, V, et al.
Publicado: (2022)

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
por: Vyas, P, et al.
Publicado: (2006)

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia
por: Jakobsen, N, et al.
Publicado: (2018)

Remission death in acute lymphoblastic leukaemia: a changing pattern.
por: Atra, A, et al.
Publicado: (1993)

Secondary acute myeloid leukaemia in children treated for acute lymphoblastic leukaemia.
por: Eden, O, et al.
Publicado: (1998)

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.
por: Guinn, B, et al.
Publicado: (2005)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
por: Dennis, M, et al.
Publicado: (2013)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
por: Lachowiez, CA, et al.
Publicado: (2023)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
por: DiNardo, CD, et al.
Publicado: (2020)

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
por: Jan, M, et al.
Publicado: (2012)